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Abstract
Objective— To examine off-label utilization and costs of antihypertensive drugs in children using
a national sample of prescription claims.
Design— Cross-sectional study.
Setting— 2002 Medstat MarketScan Database, a national sample of outpatient prescription claims
of children ?18 years old enrolled in private, employer-sponsored health plans.
Main Outcome Measures— Off-label use of antihypertensive drugs by patient age and costs of
antihypertensives calculated as mean cost per child per 30-day fill.
Results— One-half of the index antihypertensive prescription claims were off-label, based on
minimum age criteria. Boys were more likely (56%) than girls (46%) to be prescribed off-label
antihypertensives (p<0.001). Children aged ?12 years were more likely to be prescribed off-label
antihypertensives (53%) compared with children aged ?5 (46%) and 6–11 years (42%, p<0.001).
Off-label use varied significantly by class of antihypertensive drugs (p<0.001). Overall, off-label
antihypertensives were significantly more expensive than on-label antihypertensives.
Conclusions— Despite availability of often less expensive on-label alternatives for the same class
of antihypertensive drugs, off-label antihypertensive drugs were prescribed frequently in children.
These findings underscore the potential clinical and economic implications of common off-label
prescribing, for children, their parents, physicians and payers.
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INTRODUCTION
Off-label use of medications – the use of medications for an age or indication outside of the
drug label – is a common practice in pediatrics, because many medications are not labeled for
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use in children.1–9 Most studies of off-label drug use in children have been conducted in
countries outside of the United States, which have different drug licensing and regulatory
systems and therefore limited applicability to U.S. practice.6,9–14 However, a U.S. study
published in 2007 found that 79% of hospitalized children received an off-label drug; older
children were more likely to receive an off-label drug, boys were more likely than girls to
receive an off-label cardiac drug, and off-label use varied by drug class.15 In one year, off-
label use accounted for over $270 million, or 40% of the total dollars, spent on these drugs.15
We propose to study off-label use of medications in U.S. children in the outpatient setting as
a complement to this recently published inpatient study. From our study of medications listed
in the formulary of the Harriet Lane Handbook – a widely used pediatric reference source –
we know that cardiac drugs (principally antihypertensive drugs) as a class had the highest
proportion (57%) of medications without Food and Drug Administration (FDA) approved
pediatric labeling.16
Therefore, we focused on antihypertensive medications for the present study and sought to
quantify off-label use of these medications in children using a national sample of prescription
claims. We sought to describe factors associated with off-label use of antihypertensive drugs
in the outpatient setting including patient age, gender, drug cost, and class of antihypertensive
drugs. Based on the published literature,15,17–19 we hypothesized that older children and boys
would be more likely to receive off-label antihypertensive drugs than younger children and
girls respectively. We also hypothesized that there may be an economic incentive to prescribe
off-label drugs due to lower costs of older, off-patent antihypertensive medications that have
generic equivalents but not pediatric labeling. Accordingly, patterns of outpatient off-label
prescribing including variations in patient characteristics and medication costs may be
important to families and insurance plans that may be clinically and/or economically affected
by such prescribing patterns.
METHODS
Study Design
We conducted secondary analyses of cross-sectional data to examine off-label utilization and
costs of five classes of commonly used long-term antihypertensive medications (angiotensin
converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], ?-blockers,
calcium [Ca2+] channel blockers, diuretics) in children ?18 years old during a 12-month period
from January 1, 2002, to December 31, 2002. The study was approved by the Institutional
Review Board of the University of Michigan Medical School.
Data Source
We used the Medstat 2002 MarketScan Commercial Claims and Encounter Database
(Thomson Medstat Inc., Ann Arbor, MI), a nationwide database of person-level health care
utilization and expenditure data for enrollees in approximately 100 employer-sponsored benefit
plans offered by more than 40 large employers across the country. This database contains
prescription drug claims, which we used to evaluate our study’s primary objective. The
database also includes beneficiary enrollment information, although information on children’s
race/ethnicity or measures of socioeconomic status are not reported.
Study Sample
The study sample consisted of outpatient prescription claims for the five classes of commonly
used long-term antihypertensive medications among children ? 18 years old who were
continuously enrolled for >320 days during the calendar year. We identified antihypertensive
drugs individually using the variable THRDTDS (Therapeutic Detail Code Description) and
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as a class using the variable THERCLS (Therapeutic Class) from the Red Book™ files included
in the Medstat Database. Our evaluation focused on the five classes of antihypertensive drugs
(ACE inhibitors, ARBs, ?-blockers, Ca2+ channel blockers, diuretics) recommended as
acceptable classes of antihypertensive drugs for treatment of blood pressure in children by the
widely used consensus recommendations, the Fourth Report on the Diagnosis Evaluation and
Treatment of High Blood Pressure in Children, published by the National High Blood Pressure
Education Program.20 It was possible that a single patient could have multiple prescription
claims during the 12-month time frame. To mitigate the effects of possible non-independence
of prescription claims, we chose to examine only the first prescription claim in the database
for each patient during the study year which we refer to heretofore as the index prescription
claim.
Antihypertensive Medication Use
Our study had two outcomes of interest: off-label use of antihypertensive medications and the
cost of antihypertensive medications. We classified off-label use of antihypertensive drugs by
patient age criteria regardless of indication for use.15 We considered prescriptions for
antihypertensive drugs without pediatric labeling as off-label. Prescriptions for
antihypertensive drugs to children not meeting minimum age criteria on the pediatric label of
a given medication were also considered off-label; those for children meeting minimum age
criteria were considered on-label, regardless of indication. We considered all prescriptions for
antihypertensive medications with pediatric labeling, but without specific age criteria, on-label.
Thus if an antihypertensive medication was prescribed for the approved age group, but for a
condition not approved on the pediatric label, the prescription claim was still considered on-
label. We used this approach to classify off-label use because diagnoses are not reported for
each prescription claim.
We identified pediatric labeling information of each antihypertensive medication using the
drug summaries found in the Thomson Micromedex Healthcare Series, accessed online.21 To
be contemporaneous with our data source from 2002, we cross-referenced pediatric labeling
information with the FDA website providing pediatric labeling changes since 1997.22
Cost of Antihypertensive Medications
To standardize the cost measure among children with various duration of medication use, we
assessed cost of antihypertensive drugs as the mean cost per child for a 30-day supply of the
prescribed drug. The cost per child for a 30-day supply was calculated as amount paid for
prescription claim divided by (number of days of medication supply/30). Costs were assessed
among children who had no evidence of other insurance coverage in addition to the plan
represented in the Medstat Database. Children with evidence of claims having coordination of
benefits payments (i.e., with coverage from more than one payer) were assumed to have other
sources of insurance coverage and were excluded from the final dataset and cost analyses.
Analyses
We obtained descriptive statistics of the cost measure overall and for each combination of class
of antihypertensives and off-label status. We performed a two-sample t-test with equal variance
to compare off-label use and cost per child for a 30-day supply.
We used the Pearson chi-square to test bivariate comparisons between off-label use and
independent variables (age group, gender, class of antihypertensive medications). Patient age
at the time each prescription was filled was determined and classified into 3 age groups: ?5
years, 6–11 years, and ?12 years, according to commonly identified minimum age criteria for
FDA-approved pediatric use. We conducted stratified chi-square analyses between off-label
use and class of antihypertensive medications by patient gender and age group.
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To evaluate the magnitude of the associations between off-label use and class of
antihypertensive medications, we calculated adjusted odds ratios using multivariate logistic
regression controlling for patient age and gender. We chose diuretics as the reference group
for all analyses because, among the five classes of antihypertensive drugs evaluated, diuretics
had the highest proportion of medications with pediatric labeling. Similarly, we chose the oldest
age group (?12 years) as the reference group since this age group was most likely to have
pediatric indications for use of antihypertensive drugs. We hypothesized that patient age might
have distinct effects on off-label use across different classes of antihypertensive medications.
For example, all of the ARBs used in children in the youngest age group (?5 years) would be
off-label since all 6 ARBs evaluated in the study were off-label for these ages. Therefore, we
further analyzed the drug class – off-label relation stratified by age group and controlling for
gender. All results of the multivariate model are therefore shown according to age group. We
considered p-values less than 0.05 to indicate statistical significance. All statistical analyses
were conducted using STATA 8.2 (Stata Corp., College Station, TX).
RESULTS
Sample Characteristics
Of the 944,502 children in the 2002 database, 4,317 children (0.5%) had at least one
prescription claim for an antihypertensive drug. Among these children, there was a total of
19,109 prescription claims for 47 different antihypertensive medications representing the five
classes of antihypertensive drugs studied. Two-thirds of children had more than one
antihypertensive prescription claim during the study year. The final dataset included the index
prescription claim for 3,660 unique children (85% of the initial sample) for whom 1) we had
complete information on patient age, gender, drug class and drug cost and 2) there was no
evidence of coordination of benefits with additional insurance plans outside of those
represented in the database.
Among the 3,660 children who filled prescriptions for antihypertensive medications, slightly
less than half were boys (45%) and there was a preponderance (73%) of older children (?12
years). About 1 of every 7 children was prescribed 2 or more different antihypertensive drugs.
Off-Label Use of Antihypertensives for Children
One-half of the index antihypertensive prescription claims in 2002 were off-label. ?-blockers
comprised the class of antihypertensive drugs most frequently prescribed, followed by ACE
inhibitors, diuretics, Ca2+ channel blockers, and ARBs respectively (Table 1). Off-label use
varied by class of antihypertensive medications, with all Ca2+ channel blockers being
prescribed off-label compared to smaller proportions of ARBs, ACE inhibitors, ?-blockers,
and diuretics (p<0.001) (Table 1).
In bivariate analyses, children in the oldest age group (?12 years) were more likely to be
prescribed off-label antihypertensives (53%) compared to children in the youngest (?5 years)
and middle age groups (6–11 years) (46%, 42% respectively) (p<0.001). Boys were more likely
than girls to be prescribed off-label antihypertensives (56% vs. 46%) (p<0.001).
In stratified bivariate analyses, we found substantive variation in the off-label proportion by
class of antihypertensives, patient age group and gender, where the greatest variation by age
group and gender of all antihypertensives was seen in diuretics (p<0.001) (Table 2). All
Ca2+ channel blockers were off-label for all age groups and ARBs were off-label for the
youngest age group. Importantly, there were no on-label alternatives within these classes of
antihypertensives for these age groups.
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Gender-adjusted odds ratios stratified by age are presented in Table 3. All Ca2+ channel
blockers for all age groups were off-label, thus the odds ratios were indeterminate. Boys were
more likely to be prescribed off-label antihypertensive drugs compared to girls, controlling for
patient age and class of antihypertensives. For children in the oldest age group, ACE inhibitors,
ARBs, and ?-blockers were more likely to be prescribed off-label than diuretics. Conversely,
for children in the middle age group, ACE inhibitors, ARBs, and ?-blockers were less likely
to be prescribed off-label. For children in the youngest age group, ACE inhibitors and ?-
blockers were more likely to be prescribed off-label. In contrast, diuretics were significantly
less likely to be prescribed off-label in the youngest age group compared with the older age
groups.
Cost of Antihypertensives for Children
The mean cost of an antihypertensive drug per child per 30-day fill in 2002 was $22.12 (95%
CI: $21.37–$22.87). Overall, off-label antihypertensive drugs were statistically significantly
more expensive compared to on-label antihypertensives, with the mean cost of an off-label
antihypertensive per child per 30-day fill at $23.48 (95% CI: $22.26–$24.69) compared to
$20.74 (95% CI: $19.86–$21.62) for an on-label antihypertensive (p<0.001). However, we
also found that the mean cost of an off-label and on-label antihypertensive drug per child per
30-day fill varied by class of antihypertensives: off-label ?-blockers and diuretics were
significantly less expensive than same-class on-label counterparts (Table 4).
DISCUSSION
We found that one-half of children ?18 years of age for whom antihypertensive medications
were prescribed in 2002 received an off-label drug in the outpatient setting. We found that off-
label use of antihypertensives was positively associated with older age and male gender,
consistent with findings from a recent U.S. study of medication use among hospitalized
children.15 We also found that off-label antihypertensives were overall more expensive than
their on-label counterparts. To our knowledge, this is the first study of off-label use and costs
of antihypertensive medications in U.S. children in the outpatient setting. Our novel findings
raise questions about factors that influence physicians’ prescribing behavior, including patient
characteristics and the labeling status of medications.
Until recently, previous studies of off-label drug use in U.S. children were limited to simple
counts of medications listed in drug references, rather than prescriptions written for such
medications.3,7,16 Studies using the Physician’s Desk Reference (PDR) estimated that
approximately 75% of medications were off-label for use in children because they had
insufficient labeling information for pediatric use.3,7 We found in our study of pediatric
labeling status of medications listed in the formulary of the Harriet Lane Handbook that 57%
of cardiovascular medications did not have FDA–approved pediatric labeling.16
Importantly, our study indicates that even when on-label alternatives exist within the same
class of antihypertensive medications, off-label antihypertensives are still prescribed. It is
unknown whether off-label antihypertensives are prescribed because physicians are unaware
of on-label alternatives, and/or whether off-label antihypertensives are prescribed because
other potential factors such as insurance plan formularies are more influential than pediatric
labeling status in the physician choice of antihypertensive medications.
We found that children in the oldest age group were consistently more likely to be prescribed
off-label antihypertensive drugs compared to children in the youngest and middle age groups.
We speculate that adolescents may be more likely to receive off-label antihypertensive drugs
because physicians may extrapolate adult doses more frequently for this age group than for
younger children.
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Despite boys and girls being equally represented among antihypertensive users in our dataset,
we found that boys were consistently more likely to be prescribed off-label antihypertensives
compared to girls. Our finding is consistent with previous studies that have shown boys are
more likely than girls to receive off-label medications, such as growth hormone for short
stature.17–19
We found that index off-label antihypertensives overall were more expensive from the payer
perspective, compared with their on-label counterparts in 2002. However, older drugs with
expired patent protection and generic equivalents, such as diuretics and ?-blockers, were found
to be less expensive prescribed off-label compared to their on-label counterparts in the same
classes. To our knowledge, this is a novel finding not previously identified in studies of off-
label drug use in children. This finding suggests there is a possible economic incentive for off-
label antihypertensive use for diuretics and ?-blockers from the payer perspective – which adds
complexity for health plans that generally prioritize medications with generic equivalents but
may also wish to promote use of medications with pediatric labeling in their formularies.
Limitations
Our study examined filled prescription claims of antihypertensive medications. Actual patient
use of these medications may differ from patterns of use found in our study. Also, our study
used 2002 claims data which may not reflect current utilization patterns of antihypertensives
in children, because pediatric labeling changes have occurred during the interim time period.
Our conservative definition of off-label use in our analysis that did not include off-label use
by indication may have resulted in underestimation of off-label use of antihypertensive
medications in children. Our consideration of prescription claims for antihypertensive
medications approved for pediatric use without specific age criteria to be on-label for all ages
may have also resulted in underestimation of off-label use of antihypertensive medications.
In addition, our findings pertain to children enrolled in employer-sponsored benefit plans and
may not be generalizable to other children without prescription medication coverage or children
with public coverage such as Medicaid. Furthermore, we did not evaluate factors that predicted
which children would receive antihypertensive medications, particularly off-label
antihypertensives; further assessment of demographic characteristics (including race/ethnicity
and measures of socioeconomic status) is important. In addition, patterns of off-label use of
antihypertensive medications in children may be further illuminated by future investigations
of provider prescribing practices of these drugs. Finally, there were no clinical outcomes of
antihypertensive medication use available for study from this dataset.
CONCLUSIONS
Despite the availability of multiple on-label alternatives, one-half of outpatient prescription
claims for antihypertensive medications in this national sample of children were off-label in
2002. Findings from our outpatient study and the recent inpatient study of off-label use among
hospitalized children highlight the need to understand the clinical and economic implications
of frequent off-label physician prescribing practices.
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ABBREVIATIONS USED
ACE  
Angiotensin Converting Enzyme
ADHD  
Attention Deficit Hyperactivity Disorder
ARB  
Angiotensin Receptor Blocker
Ca2+  
Calcium
FDA  
Food and Drug Administration
ICD-9  
International Classification of Diseases, 9th Revision
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Table 1
Off-label Use of Antihypertensive Drugs*, by Class (n=3660)
Class of Antihypertensives n Proportion Off-label (%)
Ca2+ channel blockers 530 100
ARBs^ 80 78
ACE inhibitors 699 63
?-blockers 1740 42
Diuretics 611 12
All classes 3660 50
*
Pertains to the index prescription claim; p<0.001
^
ARBs denote Angiotensin Receptor Blockers
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Table 3
Results from Multivariate Logistic Regression Model of Off-label Use of Antihypertensive Drugs ¶ (n=3660)
OR 95% CI
Male (compared to females) 1.43 1.22–1.68
Oldest age group (?12 years)±
ᒚDiuretics 1.00 Reference
ᒚACE inhibitors 10.18 7.23–14.34
ᒚ ARBs^ 18.04 9.32–34.91
ᒚ?-blockers 4.83 3.59–6.50
ᒚCa2+ channel blockers * *
Middle age group (6–11 years)
ᒚDiuretics 0.96 0.46–2.00
ᒚACE inhibitors 0.67 0.29–1.54
ᒚ ARBs^ 0.54 0.11–2.54
ᒚ?-blockers 0.44 0.20–0.97
ᒚCa2+ channel blockers * *
Youngest age group (?5 years)
ᒚDiuretics 0.32 0.14–0.73
ᒚACE inhibitors 3.04 1.21–7.67
ᒚ ARBs^ ᒷ ᒷ
ᒚ?-blockers 3.39 1.32–8.68
ᒚCa2+ channel blockers * *
x
Odds ratios reflect the relative odds of off-label use of antihypertensive drugs controlling for patient age, gender, drug class, and age*drug class interaction
term.
s
The reference group for the age*drug class interaction is the oldest age group prescribed diuretics.
^
ARBs denote Angiotensin Receptor Blockers
*
All Ca2+ channel blockers for all age groups were off-label, thus the odds ratios were indeterminate.
ᒷ
All ARBs for the youngest age group were off-label, thus the odds ratio was indeterminate.
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Table 4
Mean Cost of Antihypertensive Drugs per Child per 30-day fill, by Class (n=3660)
Class of Antihypertensives Off-label Mean Cost (95% CI), $ On-label Mean Cost (95% CI), $
Ca2+ channel blockers 35.76 (32.60–38.93) *
ARBs^ 44.36 (41.26–47.46) 42.43 (37.04–47.81)
ACE inhibitors 25.73 (23.65–27.82) 26.01 (23.61–28.40)
?-blockers 12.71 (11.73–13.69) 18.95 (17.85–20.05)
Diuretics 12.06 (9.67–14.45) 20.82 (19.06–22.58)
*
All Ca2+ channel blockers for all age groups were off-label.
^
ARBs denote Angiotensin Receptor Blockers
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